SOURCE: BioMedReports


September 14, 2011 08:08 ET

Q&A Exclusive: Ampio's Leadership Aggressively Focused on Significant Licensing Opportunities and Getting Trials Completed

LOS ANGELES, CA--(Marketwire - Sep 14, 2011) - The low-float shares of Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) have continued their steady uptrend despite these volatile markets. Much of that appreciation may be due to the investment community's growing awareness of the small firm's impressive pipeline and strategy.

A new report featuring an exclusive interview with Michael Macaluso, the Founder and Chairman of Ampio Pharmaceuticals explores the firm focus on our significant licensing opportunities and push ahead to get clinical trials completed. That report may be read at:

In addition, investors may access BioMedReports' new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions for use as a tool in more profitable trading by visiting:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556